Skip to content

Development of NLRP3 Inflammasome Inhibitors for Neuroinflammatory Conditions

A novel small molecule drug that blocks the ATPase activity of the nucleotide-binding domain for the inhibition of inflammasome pathways

Published: 28th March 2022
Development of NLRP3 Inflammasome Inhibitors for Neuroinflammatory Conditions
Source: freshidea, https://stock.adobe.com/uk/275741212, stock.adobe.com
IP Status
  • Patent application submitted